FDA Globalization Capacity, Shortage Monitoring Remain Concerns, GAO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In updated high-risk report, GAO says resources are an issue for FDA’s globalization plans and the agency should better manage its drug shortage data.
You may also be interested in...
FDA Mutual Reliance with EU on Inspections Is Slow Going
FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.
FDA Mutual Reliance With EU On Inspections Is Slow Going
FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.
Updated: FDA Manufacturing Inspectors Could Be Further Divided Into Subspecialties
Industry could benefit from smoother plant inspections.